BIG PHARMA EARNINGS WATCH: NOVARTIS, ELI LILLY & ROCHE

Trio of Big Pharma Firms Bank Q1 Profits Driven By Price Hikes

New first quarter earnings reports from brand name drug makers Novartis, Eli Lilly, and Roche demonstrate yet again that price-hikes and anti-competitive behavior continue to drive big time profits for Big Pharma companies.

Novartis

Eli Lilly
Roche
The sky-high earnings reports come as the companies have continued to hike prices on prescription drugs in their portfolios, despite the increased economic uncertainty brought on by the pandemic and heightened scrutiny from lawmakers.

Novartis

And a recent report from the U.S. House Committee On Oversight and Reform reveals the lengths the brand name giant went to maximize profits on its blockbuster drug Gleevec.
Eli Lilly
Eli Lilly is also one of three companies that control 99 percent of the insulin market. In 1996, a 10-milliliter vial of Humalog cost $21, but today, the same vial costs patients $275. And, according to a recent report from the Senate Finance Committee:
Roche

Stay tuned this week as we continue to monitor Q1 earnings announcements from Big Pharma. Check out some key takeaways from the first round of earnings call last week HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.